Answers are grounded in this paper and cite their sources.
The incretin therapies, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors, have been developed to lower blood glucose levels in patients with Type 2 diabetes. However, in addition to being a treatment strategy to improve metabolic control, incretin therapies have shown effects independent of glycemic control, including the potential to positively impact cardiovascular events, cognitive deficits and bone mineral density. This paper outlines the non-glycemic effects of incretin therapies on cardiovascular disease, cognitive function and bone health.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: